What the revised 340B rebate pilot programme means for pharma revenue operations
The US government's revised 340B rebate pilot programme signals that pharmaceutical manufacturers need to prepare their operations for the next phase of drug discount management.
The pilot shifts how pharmaceutical manufacturers provide 340B discounts to eligible hospitals and healthcare providers. The savings for certain medications will now come in the form of rebates, rather than upfront discounts. Under this new arrangement, covered entities must purchase selected Medicare negotiation drugs at the wholesale acquisition cost (WAC) or negotiated prices, then seek a manufacturer refund for the difference to the 340B price.
This approach brings the discount structure into closer alignment with other unit-based discount arrangements, such as Medicare’s Maximum Fair Price (MFP) and Medicaid’s Drug Rebate Program (MDRP).
While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift. All manufacturers need to evaluate their capacity to collect and manage claims- and encounter-level data.
How the 340B pilot reduces duplicate discounts
The Drug Channels Institute reported that discounted purchases under the 340B programme in 2025 reached $100 billion, making it the largest source of manufacturer discounts in US channels. Professor Sayeh Nikpay’s research suggests the programme has outgrown the original intent of providing more comprehensive services to low-income and medically underserved communities.
The government has incrementally expanded the programme to include more organisations than just safety-net hospitals. And regulations now permit providers to partner with an unlimited number of third-party retail and specialty contract pharmacies. This change shifted utilisation from hospital-based, physician-administered settings toward pharmacies, which was not the original objective.
The programme’s administration mechanisms also face criticism. Federal law does not mandate how covered entities use the profit margins, so it’s unclear how much of the money directly subsidises charity care or increases patient access.
The complex system also results in drug manufacturers paying duplicate discounts. With upfront discounts, the eligibility verification happens after the medication is dispensed. Manufacturers may not have complete visibility into a drug unit’s discount history, potentially leading to manufacturers applying a 340B discount and later paying an additional Medicaid or IRA rebate claim on the same unit.
Pharma companies discover duplicates through audits and reconciliation after money has changed hands. Many occurrences are never identified and, if they are, the clawback process is arduous and often unsuccessful. Manufacturers ultimately lose billions of dollars annually. Our State of Revenue Report, for example, found that 42% of pharma leaders named 340B as one of the areas with the greatest potential for reducing revenue leakage.
The 340B pilot programme replaces retroactive clawback attempts with pre-payment verification. Unit-level claims are validated before the manufacturer issues the rebate, preventing duplicate discounts and payments on ineligible claims. The workflow requires covered entities to pay more money upfront, which has raised objections from some stakeholders.
The current pilot follows an earlier attempt to reform 340B through a rebate model. The initial effort was paused after facing legal challenges and concerns from covered entities, hospitals, and pharmacy stakeholders about the operational burden of transitioning from upfront discounts to rebates. The revised pilot incorporates a narrower scope and a more structured implementation approach.
This policy change is not an attempt to dismantle 340B. Regulators want to establish transaction-level transparency, fix regulatory conflicts, and ensure the programme serves its intended purpose.
The government will make decisions on manufacturers’ rebate plans by late September, with approved plans going live 1st January 2027.
Drug manufacturers must build claims-level data capabilities
All manufacturers should view the 340B pilot programme as a prompt to build robust transaction data capabilities, which will become a core operations requirement even for those not participating in the current pilot.
The revised 340B guidance extends beyond just shifting discount delivery. It also contains enhanced data privacy requirements, mandatory unit-level rebate payments, expanded pharmacy and medical claims data requirements, and expectations around covered entity support.
Successfully administering this rebate model requires manufacturers to:
- Securely collect and validate claims data
- Calculate rebates accurately
- Facilitate payments within required timeframes
- Manage disputes and exceptions
- Maintain complete audit documentation
Manufacturers are simultaneously managing MFP, MDRP, commercial rebates, and other drug discounting programmes, each with unique requirements, timelines, and data sources. As new policies compound complexity, the risk of inconsistent calculations, incorrect prices, and duplicate payments grows.
Overseeing these programmes independently creates fragmented data, duplicate processes, and limited visibility. The disparate systems make it difficult to validate claims and reconcile overlapping discount obligations.
Drug companies must build connected, scalable, and flexible revenue management capabilities to remain compliant and reduce losses. Transaction-level visibility and cross-programme coordination let companies cross-check a claim against every other relevant discount before paying, ensuring covered entities pay the appropriate price.
Integrated systems also create an auditable chain of evidence for a manufacturer’s decision. The centralised data supports mandated reporting, and the company can defend itself if regulators challenge a decision.
340B and other policy changes also complicate drug pricing strategies. With complete portfolio and claims-level visibility, manufacturers can understand how go-to-market decisions influence revenue and patient access. The comprehensive data set also enables AI-powered scenario modelling to determine the best approach.
While the 340B programme is only a trial run, it's an indicator of where policy is headed. As regulators place greater emphasis on transparency and transaction-level validation, manufacturers need systems that can adapt. Building a connected infrastructure benefits revenue management now and enables flexibility for future policy changes.
About the author
Michael Grosberg is the vice president of product management at Model N, responsible for life sciences products across Model N’s portfolio. Grosberg joined Model N as part of the acquisition of Deloitte’s Pricing and Contracting Solutions business in 2021 and continues to lead a team focused on regulatory compliance, revenue management, and analytics for pharmaceutical manufacturers. A data scientist and a policy wonk, Grosberg views the highly complex spaces of pharmaceutical revenue management, market access, and government pricing through the underlying data, pursuing accessibility and quality that drive commercial insights. His 15-year career spans roles in public policy, analytics, systems implementation, and change management. He has broad expertise in financial performance management and led development and implementation of pharmaceutical gross-to-net applications for multiple top-tier manufacturers.
